ID: ALA4549682

Max Phase: Preclinical

Molecular Formula: C15H13Cl2NO2

Molecular Weight: 310.18

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ccc(CNC(=O)c2ccc(Cl)c(Cl)c2)cc1

Standard InChI:  InChI=1S/C15H13Cl2NO2/c1-20-12-5-2-10(3-6-12)9-18-15(19)11-4-7-13(16)14(17)8-11/h2-8H,9H2,1H3,(H,18,19)

Standard InChI Key:  IHMRPLIOWCIAJT-UHFFFAOYSA-N

Associated Targets(non-human)

Phosphodiesterase 5A 420 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 310.18Molecular Weight (Monoisotopic): 309.0323AlogP: 3.93#Rotatable Bonds: 4
Polar Surface Area: 38.33Molecular Species: NEUTRALHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 3.82CX LogD: 3.82
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.93Np Likeness Score: -1.49

References

1. Bollenbach M, Lugnier C, Kremer M, Salvat E, Megat S, Bihel F, Bourguignon JJ, Barrot M, Schmitt M..  (2019)  Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.,  177  [PMID:31158744] [10.1016/j.ejmech.2019.05.026]

Source